The EU Court of Justice confirms the pay-for-delay infringement decision in the pharmaceutical sector (Lundbeck)

On 25 March 2021, the European Court of Justice (“ECJ”) dismissed all appeals against the 2016 rulings of the General Court which had upheld the European Commission’s (“Commission”) decision to fine Lundbeck and four generic pharmaceutical companies (Merck, Alpharma, Arrow and Ranbaxy) for concluding “pay-for-delay” patent settlement agreements in breach of Article 101 Treaty on the Functioning of the European Union (“TFEU”) (Cases C-586/16 P, Sun Pharmaceutical Industries and Ranbaxy (UK) v Commission; C-588/16 P, Generics (UK) v Commis- sion; C-591/16 P, Lundbeck v Commission; C-601/16 P, Arrow Group and Arrow Generics v Commission; C-611/16 P, Xellia Pharmaceuticals

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Van Bael & Bellis (Brussels)

Quotation

Steve Ross, The EU Court of Justice confirms the pay-for-delay infringement decision in the pharmaceutical sector (Lundbeck), 25 March 2021, e-Competitions April 2021 - II, Art. N° 100250

Visites 240

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues